DK3801524T3 - Farmaceutisk sammensætning og fremgangsmåde til behandling af kræft associeret med egfr-mutation - Google Patents

Farmaceutisk sammensætning og fremgangsmåde til behandling af kræft associeret med egfr-mutation

Info

Publication number
DK3801524T3
DK3801524T3 DK19810149.5T DK19810149T DK3801524T3 DK 3801524 T3 DK3801524 T3 DK 3801524T3 DK 19810149 T DK19810149 T DK 19810149T DK 3801524 T3 DK3801524 T3 DK 3801524T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical composition
treating cancer
cancer associated
egfr mutation
egfr
Prior art date
Application number
DK19810149.5T
Other languages
Danish (da)
English (en)
Inventor
Lan Huang
George Kenneth Lloyd
Original Assignee
Beyondspring Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beyondspring Pharmaceuticals Inc filed Critical Beyondspring Pharmaceuticals Inc
Application granted granted Critical
Publication of DK3801524T3 publication Critical patent/DK3801524T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK19810149.5T 2018-06-01 2019-05-30 Farmaceutisk sammensætning og fremgangsmåde til behandling af kræft associeret med egfr-mutation DK3801524T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862679619P 2018-06-01 2018-06-01
PCT/US2019/034726 WO2019232257A1 (en) 2018-06-01 2019-05-30 Composition and method of treating cancer associated with egfr mutation

Publications (1)

Publication Number Publication Date
DK3801524T3 true DK3801524T3 (da) 2026-02-02

Family

ID=68696755

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19810149.5T DK3801524T3 (da) 2018-06-01 2019-05-30 Farmaceutisk sammensætning og fremgangsmåde til behandling af kræft associeret med egfr-mutation

Country Status (11)

Country Link
US (2) US20210161888A1 (cg-RX-API-DMAC7.html)
EP (1) EP3801524B1 (cg-RX-API-DMAC7.html)
JP (1) JP7500438B2 (cg-RX-API-DMAC7.html)
KR (1) KR102790127B1 (cg-RX-API-DMAC7.html)
CN (1) CN112543636B (cg-RX-API-DMAC7.html)
AU (1) AU2019278886B2 (cg-RX-API-DMAC7.html)
CA (1) CA3101612A1 (cg-RX-API-DMAC7.html)
DK (1) DK3801524T3 (cg-RX-API-DMAC7.html)
ES (1) ES3060133T3 (cg-RX-API-DMAC7.html)
MX (1) MX420412B (cg-RX-API-DMAC7.html)
WO (1) WO2019232257A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1249052A1 (zh) 2015-03-06 2018-10-26 BeyondSpring Pharmaceuticals Inc. 治疗与ras突变相关的癌症的方法
EP3334726B1 (en) 2015-07-13 2022-03-16 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
US10912748B2 (en) 2016-02-08 2021-02-09 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
CN109475524A (zh) 2016-06-06 2019-03-15 万春药业公司 用于减少中性粒细胞减少症的组合物和方法
WO2018129381A1 (en) 2017-01-06 2018-07-12 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
KR20190109479A (ko) 2017-02-01 2019-09-25 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증의 감소 방법
WO2019147615A1 (en) 2018-01-24 2019-08-01 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia via the administration of plinabulin
EP4319751A4 (en) 2021-04-09 2025-02-26 Beyondspring Pharmaceuticals, Inc. THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS
CN113456643B (zh) * 2021-08-11 2022-04-01 遵义医科大学 一种含普那布林的药物组合及其应用
AU2022357570A1 (en) * 2021-10-03 2024-04-11 Systimmune, Inc. Methods of treating cancer and the pharmaceutical compositions thereof
CN117860672A (zh) * 2022-10-11 2024-04-12 大连万春布林医药有限公司 一种普那布林胶束组合物及其制备方法
CN121311228A (zh) * 2023-06-02 2026-01-09 万春药业公司 肿瘤联合治疗和使用方法
CN120682197A (zh) * 2024-03-19 2025-09-23 大连万春布林医药有限公司 普那布林的盐晶型

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003302721B2 (en) * 2002-08-02 2009-10-08 Beyondspring Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
US20120114658A1 (en) * 2009-09-15 2012-05-10 John Ryan Treatment of cancer
EA201200486A1 (ru) * 2009-09-15 2012-08-30 Серулин Фарма Инк. Лечение онкологических заболеваний
SG11201505896YA (en) * 2013-02-20 2015-09-29 Novartis Ag Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
MX394865B (es) * 2015-02-12 2025-03-24 Beyondspring Pharmaceuticals Inc Uso de plinabulina en combinación con inhibidores de punto de control inmunitario
HK1249052A1 (zh) * 2015-03-06 2018-10-26 BeyondSpring Pharmaceuticals Inc. 治疗与ras突变相关的癌症的方法
BR112019018880A2 (pt) * 2017-03-13 2020-04-14 Beyondspring Pharmaceuticals, Inc. composições de plinabulina e seu uso

Also Published As

Publication number Publication date
KR20210015875A (ko) 2021-02-10
AU2019278886B2 (en) 2025-03-20
JP2021525768A (ja) 2021-09-27
JP7500438B2 (ja) 2024-06-17
US20210161888A1 (en) 2021-06-03
CA3101612A1 (en) 2019-12-05
MX420412B (es) 2025-02-10
WO2019232257A1 (en) 2019-12-05
AU2019278886A1 (en) 2020-12-24
CN112543636A (zh) 2021-03-23
MX2020012799A (es) 2021-03-25
KR102790127B1 (ko) 2025-04-03
ES3060133T3 (en) 2026-03-25
EP3801524B1 (en) 2025-11-05
EP3801524A4 (en) 2022-03-02
US20250375440A1 (en) 2025-12-11
EP3801524A1 (en) 2021-04-14
CN112543636B (zh) 2024-03-01

Similar Documents

Publication Publication Date Title
EP3838803A4 (en) DISTRIBUTION AGENCY AND DISTRIBUTION METHOD
EP3869985A4 (en) COMPOSITION AND METHOD OF TREATMENT OF THE LUNGS
DK4075992T3 (da) Isoleret oleosomsammensætning og fremgangsmåde til fremstilling heraf
DK3902803T3 (da) Aza-heterobicykliske inhibitorer af mat2a og anvendelsesfremgangsmåder til behandling af kræft
DK3826667T3 (da) Claudin6-antistoffer og fremgangsmåder til behandling af kræft
DK4028010T3 (da) Vs-6063 i kombination med ch5126766 til behandlingen af kræft
DK3880660T3 (da) Forbindelser og sammensætninger til behandling af tilstande forbundet med nlrp-aktivitet
DK3558997T3 (da) Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer
DK3455259T5 (da) Kombination af anti-PD-1-antistoffer og stråling til cancerbehandling
DK4279084T3 (da) Materialer og fremgangsmåder til behandling af duchennes muskeldystrofi
DK3565844T3 (da) Fremgangsmåder til behandling af cancer med anti-PD-1-antistoffer
DK3386518T3 (da) Metoder og sammensætninger til behandling af en serpinc1-associeret forstyrrelse
DK3810281T3 (da) Fremgangsmåder til behandling af cancer med bispecifikke antI-CD3XMUC16-antistoffer og anti-PD-1-antistoffer
DK4169491T3 (da) Indretninger og fremgangsmåde til behandling af bruxisme
DK4434585T3 (da) Forbindelser og fremgangsmåder til reduktion af snca-ekspression
DK3250210T3 (da) Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser
DK3519049T3 (da) Sikker og effektiv fremgangsmåde til behandling af psoriasis med specifikt anti-il23-antistof
DK3704227T3 (da) Sammensætning og fremgangsmåde
DK3200815T3 (da) Fremgangsmåder og sammensætninger til behandling af cancer
DK3807316T3 (da) Sammensætninger og fremgangsmåder til behandling af cancer
DK4004022T3 (da) Materialer og fremgangsmåder til behandling af friedreichs ataksi
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
DK3481856T3 (da) Materialer og metoder til behandling af smerterelaterede lidelser
DK3405728T3 (da) U-formet forbrænder og metode til anvendelse i cementfabrikker
DK3110446T3 (da) Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme